// App-Quantinova.ai

: A Risk Model for CML Patients with COVID-19: Importance of Molecular Response in the Context of Age, Comorbidities and Country Income

Researchers

Presenter

  • Jerald P. Radich

Principal Investigators

  • Chung Hoow Kok

  • Ekaterina Yu. Chelysheva

  • Jorge E. Cortes

  • Qian Jiang

  • Michael Mauro

  • Dragana Milojkovic

  • Beatriz Moiraghi

  • Franck E. Nicolini

  • Matilda Ongondi

  • Katia B Pagnano

  • Daniela Zackova

  • Delphine Rea

  • Nicola Evans

  • Timothy Hughes

Medical Centers

  • Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, Beijing, China

  • Université de Paris, Hematology department, Saint-Louis hospital, APHP, Paris, France

  • South Australian Health and Medical Research Institute SAHMRI, Adelaide, Australia

  • Precision Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, Australia

  • International CML Foundation, Bexhill On Sea, United Kingdom

  • Georgia Cancer Center, Augusta, GA

  • Memorial Sloan Kettering Cancer Center, New York, NY

  • Hospital General De Agudos J.M. Ramos Mejia, Buenos Aires, Argentina

  • Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom

  • Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA

  • Hematology and Hemotherapy Center, University of Campinas, Campinas, Brazil

  • Internal Hematology and Oncology Clinic, University Hospital Brno and Masaryk University, Brno, Czech Republic

  • National Medical Research Center for Hematology, Moscow, AZ

  • Centre Hospitalier Lyon Sud, LYON Cedex , France

  • Kenyatta National Hospital, Nairobi, KEN

Locations

  • China

  • United Kingdom

  • United States

  • France

  • Australia

  • Brazil

  • Kenya

  • Argentina

  • Czech Republic

Companies

  • N/A

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

Disease

  • Coronavirus disease

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved